Thymosin Alpha-1 Peptide Guide: TLR9 Immunomodulator Mechanism, Zadaxin Approval Map, and Research Applications

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

What is Thymosin Alpha-1?

Thymosin Alpha-1 (also written Tα1, Thymalfasin, or the brand name Zadaxin) is a synthetic acetylated 28-amino-acid peptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, identified in the chemical literature by CAS 62304-98-7 and molecular weight 3108 Da.

The peptide was isolated from calf thymus in the 1970s by Allan Goldstein’s laboratory at Albert Einstein and later George Washington University, in work that established the existence of a thymus-derived immunomodulatory polypeptide family. It was the first thymic peptide synthesised chemically and the first taken to phase-3 clinical trials. The chemically synthetic form is identical to the endogenous fragment, which is why the same compound underpins both the marketed medicine (Zadaxin, Thymalfasin) and the research-grade laboratory reagent.

Tα1 is structurally and pharmacologically distinct from the better-known Thymosin Beta-4 (TB-500) — the two share “thymosin” in their name because both were originally isolated from the same thymic extract (Thymosin Fraction 5), but the alpha and beta families differ in size, structure and mechanism. Tα1 acts on the immune system via TLR9 signalling on dendritic cells; TB-500 acts on actin polymerisation in connective and vascular tissues. They are not interchangeable, and they do not stack additively.

If you are mapping the broader peptide landscape, Tα1 sits in the immunomodulator family alongside compounds such as KPV (Lysine-Proline-Valine), the cathelicidin LL-37, and the broader thymic-peptide bioregulator family that includes Thymalin. The MedsBase peptide hub groups all 39 research peptides into clinical-research clusters.

Origin in prothymosin alpha and why the fragment matters

Endogenous Tα1 is not synthesised as an independent peptide. It is generated by proteolytic processing of the much larger 109-amino-acid nuclear protein prothymosin alpha (ProTα), which is itself involved in nuclear chromatin regulation and cell proliferation. The N-terminal 28 amino acids of ProTα are cleaved off under specific physiological conditions to release the bioactive Tα1 fragment.

The pharmacological significance of this origin is two-fold. First, Tα1 is not stored in granules and released on demand like a classical hormone — its plasma levels rise in response to immune challenge as ProTα processing accelerates. Second, the parent protein ProTα itself has immune-signalling activity independent of Tα1 cleavage, and some published research describes ProTα as a damage-associated molecular pattern (DAMP) released by dying cells. The receptor biology and signalling consequences of the parent protein and the cleavage fragment are partly overlapping and partly distinct.

For the academic background on Tα1 as a phenotypic drug-discovery target and the broader thymic-peptide biology, the 2024 review by King and Tuthill (PMID 38903817, Frontiers in Medicine) is the most current comprehensive reference.

Mechanism — TLR9 signalling on dendritic cells

The single most established molecular mechanism for Tα1 was published by the Romani laboratory in 2007. They demonstrated that Tα1 activates Toll-like receptor 9 (TLR9) on plasmacytoid dendritic cells, with downstream signalling through the canonical MyD88 / IRF7 pathway leading to induction of indoleamine 2,3-dioxygenase (IDO) and the type-1 interferon response (Romani L et al., International Immunology 2007, PMID 17804687).

That mechanism is unusual in two ways:

1. TLR9 is the canonical receptor for unmethylated CpG bacterial DNA. Tα1 is a peptide, not a nucleic acid — the agonism is non-canonical. The current published interpretation is that Tα1 binds the dimerisation interface of TLR9 rather than the CpG-DNA binding pocket, producing a receptor-active conformation through allosteric stabilisation.
2. The downstream effect is not pro-inflammatory. Classical TLR9 agonism by CpG DNA produces a strong type-1 interferon and pro-inflammatory cytokine response. Tα1 agonism produces a more nuanced output: type-1 interferon is induced, but IDO activation drives concurrent T-regulatory-cell expansion, which dampens inflammation rather than amplifying it.

The net effect is what immunologists describe as “immune recalibration” rather than “immune stimulation” or “immune suppression”. The 2018 review by Camerini and Garaci (PMID 30063867, Expert Opinion on Biological Therapy) covers the full mechanistic and clinical-research case.

T-cell modulation — recalibration, not stimulation

Downstream of the dendritic-cell TLR9 trigger, Tα1 affects T-cell biology at multiple points. The published research describes:

• Improved T-cell maturation — Tα1 promotes maturation of CD3+ thymocytes into CD4+ helper and CD8+ cytotoxic populations in animal models of thymic involution or chemotherapy-induced lymphocyte depletion.
• Shift in Th1/Th2 balance — in chronic viral-infection models Tα1 increases the Th1/Th2 ratio (more interferon-gamma, less IL-4), enhancing cell-mediated immunity against intracellular pathogens.
• Restored CD4/CD8 ratio — Tα1 partially restores the CD4/CD8 ratio in HIV-research models and in aged-immune-system models of T-cell senescence.
• Enhanced NK-cell cytotoxicity — secondary effect via the type-1 interferon arm of the dendritic-cell signal.
• Expansion of regulatory T cells (Tregs) — via the IDO arm of the dendritic-cell signal. This is the “tone-correcting” arm that distinguishes Tα1 from classical immune stimulants.

The 2023 review by Costantini and colleagues (PMID 37110771, Molecules 2023) lays out the clinical-research applications across viral infection, while the 2023 review of Tα1 in lung cancer mechanism (PMID 37701432, Frontiers in Immunology) covers the cancer-adjunct line of research.

Zadaxin approval map — where Tα1 is a medicine

Tα1 is one of a small number of peptides where the same chemical compound has a split regulatory status worldwide. The approved-medicine status, where it exists, is the Zadaxin (or local equivalent “Thymalfasin”) brand. The approval landscape as of 2026:

This split status is unusual and is the reason almost all primary clinical-research literature on Tα1 originates from Italy and China — those are the two jurisdictions where the compound has been simultaneously available as a marketed medicine and as a research probe for two decades.

Chronic hepatitis B research history

The original and largest clinical-research dataset on Tα1 covers chronic hepatitis B (HBV). Multiple controlled trials between 1995 and 2010 demonstrated that Tα1 monotherapy at 1.6 mg subcutaneous twice weekly for 24–26 weeks achieves HBeAg seroconversion rates of roughly 25–40%, comparable to interferon-alpha but with a substantially better tolerability profile (no flu-like syndrome, no significant haematological toxicity).

Combination regimens with interferon-alpha and later with nucleos(t)ide analogues (lamivudine, entecavir, tenofovir) have also been studied, with most reports suggesting additive but not synergistic activity. The 2023 lung-cancer review (PMID 37701432) summarises the mechanistic case for combination with conventional therapies in viral and oncologic indications. The full PubMed body of work on Tα1 across all indications can be browsed at the PubMed search for “thymosin alpha-1”, which returns roughly 1,400 papers spanning the entire research history.

Background on hepatitis B itself and the broader immune-response landscape against chronic viral hepatitis is maintained at the MedlinePlus Immune System and Disorders page.

Cancer-adjunct research

The second-largest body of Tα1 clinical research covers cancer-adjunct settings — particularly:

• Stage 4 melanoma — Tα1 in combination with dacarbazine and interferon-alpha, studied in Italian multicentre trials in the 2000s. The combination produced response rates of roughly 22–25% versus 6–12% for the conventional comparator arms.
• Non-small-cell lung cancer (NSCLC) — Tα1 as adjuvant immunomodulator after surgical resection, with a focus on restoration of T-cell counts and reduction in post-operative infection rates.
• Hepatocellular carcinoma (HCC) — Tα1 as adjunct after transarterial chemoembolisation, with reported reductions in chemotherapy-induced lymphopenia.
• Vaccine response in cancer patients — Tα1 as adjuvant for influenza and hepatitis vaccines in chemotherapy-immunosuppressed patients, where vaccine seroconversion rates are markedly reduced.

The mechanism in oncology contexts is consistent with the dendritic-cell TLR9 mechanism described above: Tα1 partially restores tumour-antigen presentation and CD8+ effector T-cell function suppressed by chemotherapy. It is best understood as an immune-restoration agent rather than a direct anti-tumour agent — it does not kill tumour cells directly, it restores the host’s capacity to do so.

Sepsis and aged-immunity research

Severe sepsis is a state of paradoxical immune dysregulation — an initial pro-inflammatory cytokine storm followed by a compensatory anti-inflammatory state with profound T-cell exhaustion. Tα1’s “tone-correcting” pharmacology has therefore been studied as a candidate in the post-cytokine-storm phase of sepsis.

The largest published trial is the ETASS (Efficacy of Thymosin alpha 1 for Severe Sepsis) randomised controlled trial conducted in China and published in 2013, which enrolled 361 patients and reported reduced 28-day mortality with Tα1 added to standard sepsis care. Subsequent meta-analyses have produced mixed results, with overall benefit consistently driven by the subset of patients with documented lymphopenia (the “immune-paralysed” phenotype) rather than the broader sepsis population.

A parallel line of research covers aged-immunity restoration — the “immunosenescence” that develops with age as the thymus involutes and central T-cell output declines. Animal-model work suggests Tα1 partially restores naive-T-cell repertoires; human data is more limited but consistent in direction. Broader background on the thymus and immune development is maintained at the NCBI Bookshelf chapter on Janeway’s Immunobiology (NBK6028).

Routes, dosing schedules and pharmacokinetics

Tα1 has been studied across three administration routes; subcutaneous dominates the published clinical-research literature.

The pharmacokinetic-versus-pharmacodynamic mismatch is one of Tα1’s most important features for research design: the plasma half-life is short (~2 hours) but the biological signal persists 3–4 days. This is because the readout is downstream T-cell maturation and Treg expansion, both of which are slow cellular processes that continue long after the inducing dendritic-cell signal has decayed. Twice-weekly dosing is therefore adequate, and more frequent dosing produces no measurable additional effect.

For broader context on selecting peptide administration routes — bioavailability, onset, sterile-handling implications — see our Peptide Injection Routes guide (SC, IM, intranasal). Tα1 is a relatively simple case: subcutaneous, twice weekly, no cycling required for tolerance.

Reconstitution, storage and laboratory handling

Tα1 is supplied as a sterile lyophilised acetate powder. Standard laboratory reconstitution practice:

• Diluent: bacteriostatic water (0.9% benzyl alcohol) for multi-use reconstitution, or sterile water for injection for single-use research.
• Concentration: typically 1 mg/mL or 1.6 mg/mL for clinical-research-equivalent dosing.
• pH: reconstituted solution pH 5–7; outside this range degradation accelerates.
• Storage of lyophilised powder: −20°C protected from light; stable 24+ months unopened. The acetylated N-terminus stabilises the peptide significantly compared to non-acetylated peptides.
• Storage of reconstituted solution: 2–8°C; use within 14 days for bacteriostatic-water reconstitution, within 7 days for sterile-water reconstitution.
• Avoid: repeated freeze–thaw cycles of reconstituted material; vortexing (use gentle inversion to redissolve).

The full laboratory-handling protocol is set out in the Peptide Storage & Cold-Chain guide, and reconstitution-volume mathematics for arbitrary dose/concentration targets is covered in How to Reconstitute Peptides.

Research-grade sourcing — what to look for on a COA

A defensible research-grade Certificate of Analysis (COA) for Tα1 will document at minimum:

1. Identity — mass spectrometry confirmation of the molecular ion. Theoretical monoisotopic mass for Tα1 (N-acetylated): 3108.3 Da. Observed [M+H]⁺ ~3109 Da; commonly reported as [M+2H]²⁺ at m/z ~1555 due to instrument range.
2. Purity — RP-HPLC purity ≥99% at 220 nm absorbance, with the chromatogram included in the COA. Single significant impurity peak <0.5%.
3. N-terminal acetylation confirmation — specific to Tα1: the unmodified 28-amino-acid peptide is a common synthesis impurity and is biologically distinct from the acetylated active form. Mass-spec should confirm the +42 Da acetyl mass shift.
4. Counter-ion — acetate content (typically 5–10% by mass).
5. Water content — Karl Fischer titration <8%.
6. Endotoxin — LAL test <1 EU/mg for products intended for in-vivo research use.
7. Bacterial bioburden — <100 CFU/g.
8. CAS number — 62304-98-7. Anything else is mislabelled.

The methodology for reading and verifying any peptide COA is set out in our dedicated How to Read a Peptide COA guide.

MedsBase supplies Thymosin Alpha-1 (Thymalfasin) as a research-grade laboratory reagent from a WHO-GMP-certified manufacturer, with HPLC purity ≥99%, full batch COA on file, mass-spec confirmation of the N-terminal acetylation, and CAS-keyed labelling. Worldwide Shipping. The compound is supplied for laboratory and research use only.

Frequently Asked Questions

Is Thymosin Alpha-1 the same as Zadaxin?

Yes, in terms of chemical identity. Zadaxin (international trade name) and Thymalfasin (international non-proprietary name) refer to the same 28-amino-acid acetylated peptide as Tα1, CAS 62304-98-7. The difference is regulatory rather than chemical: Zadaxin is the marketed-medicine form, dispensed in glass ampoules with a sterile-water diluent and approved-medicine packaging; research-grade Tα1 is the same molecular entity supplied as lyophilised powder for laboratory use.

Is Tα1 the same as Thymosin Beta-4 (TB-500)?

No — same family name, completely different molecule and mechanism. Thymosin Alpha-1 is a 28-amino-acid peptide that acts as an immunomodulator via TLR9 on dendritic cells. Thymosin Beta-4 (TB-500) is a 43-amino-acid peptide that acts on actin polymerisation, with research applications in tissue healing, angiogenesis and connective-tissue repair. The two share “thymosin” in their name because both were originally co-isolated from calf thymus extract (Thymosin Fraction 5) in the 1970s.

Why does Tα1 not cause flu-like syndrome like interferon?

Because the type-1 interferon induction is more localised and concurrent with IDO-driven T-regulatory expansion. The dendritic-cell TLR9 signal that Tα1 produces yields a net immune output that is biased toward immune-tone correction rather than systemic inflammation. Interferon-alpha given as a medicine bypasses this regulatory loop entirely and produces a much stronger pro-inflammatory output, which is what the patient experiences as the flu-like syndrome.

What is the relationship between Tα1 and HIV research?

HIV depletes CD4+ T-helper cells and inverts the normal CD4/CD8 ratio. Tα1 has been studied as an adjunct in HIV research on the logic that its CD4/CD8 ratio restoring effect in animal models might partially compensate. Small trials in the 1990s and 2000s produced modest signal, but Tα1 was overtaken by the much larger effect sizes available from combination antiretroviral therapy and was not pursued as a primary HIV intervention. It remains an active research topic in the immune-reconstitution literature.

How does Tα1 compare to KPV as an immunomodulator?

Different molecular weights, different mechanisms, different research niches. KPV is a 3-amino-acid C-terminal fragment of alpha-MSH that acts directly as an anti-inflammatory at the cellular level, with research focus on gut inflammation and mucosal repair (and significant overlap with the BPC-157 gut-research literature). Tα1 is a 28-amino-acid immune-recalibrator with research focus on systemic immune dysregulation (chronic viral infection, cancer adjunct, sepsis). They are not interchangeable.

Can Tα1 be combined with other peptides?

The published clinical-research literature on Tα1 combinations is almost entirely with conventional medicines (interferon-alpha, nucleos(t)ide analogues, chemotherapy regimens) rather than other research peptides. Combinations with other immunomodulator peptides (LL-37, KPV) have not been systematically studied. The general principle — do not combine compounds with overlapping mechanisms without specific mechanistic justification — is set out in our Peptide Blends Explained guide.

Does Tα1 require cycling like GHRPs?

No. Unlike GHSR-1a agonists (the GHRP family) which down-regulate their receptor on chronic dosing, Tα1’s TLR9 mechanism does not show receptor-level tachyphylaxis in any reported research. The full clinical-research dataset includes 24-week and 52-week continuous-dosing protocols without loss of activity. Cycling is not required for tolerance; some research protocols cycle anyway to reduce cost or to study the kinetics of effect decay, but the mechanistic rationale that applies to growth-hormone secretagogues (covered in our Peptide Cycling Protocols guide) does not apply here.

Where do I find the original mechanism papers?

The two foundational mechanistic papers are Romani et al. 2007 (PMID 17804687) on the TLR9 / MyD88 / IRF7 dendritic-cell mechanism, and Camerini & Garaci 2018 (PMID 30063867) on the “cellular proteostasis” framing that integrates the immunomodulatory and parent-protein-derived effects. For current clinical-research applications start with Costantini et al. 2023 (PMID 37110771) on viral indications. The full body of work is browsable at the PubMed search for thymosin alpha-1.

Outbound research references in this guide: PMID 17804687 — Romani 2007 TLR9 mechanism · PMID 30063867 — Camerini & Garaci 2018 proteostasis · PMID 37110771 — Costantini 2023 viral infections · PMID 37701432 — Tα1 in lung cancer mechanism 2023 · PMID 38903817 — King & Tuthill 2024 phenotypic drug discovery · PubMed: all thymosin alpha-1 papers · NCBI Bookshelf — Janeway’s Immunobiology · MedlinePlus — Immune system and disorders.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.